208 related articles for article (PubMed ID: 31742892)
1. Systematic screening identifies a 2-gene signature as a high-potential prognostic marker of undifferentiated pleomorphic sarcoma/myxofibrosarcoma.
Hu Q; Zhou S; Hu X; Zhang H; Huang S; Wang Y
J Cell Mol Med; 2020 Jan; 24(1):1010-1021. PubMed ID: 31742892
[TBL] [Abstract][Full Text] [Related]
2. Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival.
Li GZ; Okada T; Kim YM; Agaram NP; Sanchez-Vega F; Shen Y; Tsubokawa N; Rios J; Martin AS; Dickson MA; Qin LX; Socci ND; Singer S
Cancer Res; 2020 Jun; 80(12):2461-2471. PubMed ID: 32161142
[TBL] [Abstract][Full Text] [Related]
3. Comparative Study of Myxofibrosarcoma With Undifferentiated Pleomorphic Sarcoma: Histopathologic and Clinicopathologic Review.
Yoshimoto M; Yamada Y; Ishihara S; Kohashi K; Toda Y; Ito Y; Yamamoto H; Furue M; Nakashima Y; Oda Y
Am J Surg Pathol; 2020 Jan; 44(1):87-97. PubMed ID: 31651522
[TBL] [Abstract][Full Text] [Related]
4. Optimal Percent Myxoid Component to Predict Outcome in High-Grade Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma.
Lee AY; Agaram NP; Qin LX; Kuk D; Curtin C; Brennan MF; Singer S
Ann Surg Oncol; 2016 Mar; 23(3):818-25. PubMed ID: 26759307
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of an immune gene-set based prognostic signature for soft tissue sarcoma.
Shen R; Liu B; Li X; Yu T; Xu K; Ma J
BMC Cancer; 2021 Feb; 21(1):144. PubMed ID: 33557781
[TBL] [Abstract][Full Text] [Related]
6. The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.
Ishihara S; Iwasaki T; Kohashi K; Yamada Y; Toda Y; Ito Y; Susuki Y; Kawaguchi K; Takamatsu D; Kawatoko S; Kiyozawa D; Mori T; Kinoshita I; Yamamoto H; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2003-2011. PubMed ID: 33811537
[TBL] [Abstract][Full Text] [Related]
7. Pan-cancer Genomic Analysis of AXL Mutations Reveals a Novel, Recurrent, Functionally Activating AXL W451C Alteration Specific to Myxofibrosarcoma.
Williams EA; Vegas I; El-Senduny FF; Zhang J; Mata DA; Hiemenz MC; Hughes SR; Sa BC; Kraft GP; Gorbatov N; Foley-Peres K; Sanchez EZ; Milikowski C; Williams KJ; Ross JS; Kurzrock R; Montgomery EA; Lombard DB; Kumar S
Am J Surg Pathol; 2024 Jun; 48(6):699-707. PubMed ID: 38369783
[TBL] [Abstract][Full Text] [Related]
8. MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma.
Conley AP; Wang WL; Livingston JA; Ravi V; Tsai JW; Ali A; Ingram DR; Lowery CD; Roland CL; Somaiah N; Hwu P; Yee C; Subbiah V; Futreal A; Lazar AJ; Patel S; Roszik J
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31096717
[TBL] [Abstract][Full Text] [Related]
9. Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma.
Okada T; Lee AY; Qin LX; Agaram N; Mimae T; Shen Y; O'Connor R; López-Lago MA; Craig A; Miller ML; Agius P; Molinelli E; Socci ND; Crago AM; Shima F; Sander C; Singer S
Cancer Discov; 2016 Oct; 6(10):1148-1165. PubMed ID: 27577794
[TBL] [Abstract][Full Text] [Related]
10. Impact of infiltrative growth on the outcome of patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma.
Iwata S; Yonemoto T; Araki A; Ikebe D; Kamoda H; Hagiwara Y; Ishii T
J Surg Oncol; 2014 Nov; 110(6):707-11. PubMed ID: 24975462
[TBL] [Abstract][Full Text] [Related]
11. Periostin and Epithelial-Mesenchymal Transition Score as Novel Prognostic Markers for Leiomyosarcoma, Myxofibrosarcoma, and Undifferentiated Pleomorphic Sarcoma.
Piano MA; Brunello A; Cappellesso R; Del Bianco P; Mattiolo A; Fritegotto C; Montini B; Zamuner C; Del Fiore P; Rastrelli M; Sommariva A; De Salvo GL; Montesco MC; Rossi CR; Zagonel V; Calabrò ML
Clin Cancer Res; 2020 Jun; 26(12):2921-2931. PubMed ID: 32127392
[TBL] [Abstract][Full Text] [Related]
12. LMX1B mRNA expression and its gene body CpG methylation are valuable prognostic biomarkers for laryngeal squamous cell carcinoma.
Fan L; Zhang A; Deng P
Biomed Pharmacother; 2019 Sep; 117():109174. PubMed ID: 31387183
[TBL] [Abstract][Full Text] [Related]
13. OSmfs: An Online Interactive Tool to Evaluate Prognostic Markers for Myxofibrosarcoma.
Li H; Xie L; Wang Q; Dang Y; Sun X; Zhang L; Han Y; Yan Z; Dong H; Zheng H; Li Y; Zhu W; Guo X
Genes (Basel); 2020 Dec; 11(12):. PubMed ID: 33352742
[TBL] [Abstract][Full Text] [Related]
14. Management of Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma.
Crago AM; Cardona K; Koseła-Paterczyk H; Rutkowski P
Surg Oncol Clin N Am; 2022 Jul; 31(3):419-430. PubMed ID: 35715142
[TBL] [Abstract][Full Text] [Related]
15. Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives.
Widemann BC; Italiano A
J Clin Oncol; 2018 Jan; 36(2):160-167. PubMed ID: 29220302
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Factors and Outcomes for Patients With Myxofibrosarcoma: A 13-Year Retrospective Evaluation.
Mühlhofer HML; Lenze U; Gersing A; Lallinger V; Burgkart R; Obermeier A; VON Eisenhart-Rothe R; Knebel C
Anticancer Res; 2019 Jun; 39(6):2985-2992. PubMed ID: 31177139
[TBL] [Abstract][Full Text] [Related]
17. Identification of a survival-related signature for sarcoma patients through integrated transcriptomic and proteomic profiling analyses.
Zhang B; Yang L; Wang X; Fu D
Gene; 2021 Jan; 764():145105. PubMed ID: 32882333
[TBL] [Abstract][Full Text] [Related]
18. The Biology of Myxofibrosarcoma: State of the Art and Future Perspectives.
Sambri A; De Paolis M; Spinnato P; Donati DM; Bianchi G
Oncol Res Treat; 2020; 43(6):314-322. PubMed ID: 32450554
[TBL] [Abstract][Full Text] [Related]
19. Surgical margins do not affect prognosis in high grade myxofibrosarcoma.
Sambri A; Bianchi G; Righi A; Ferrari C; Donati D
Eur J Surg Oncol; 2016 Jul; 42(7):1042-8. PubMed ID: 27260849
[TBL] [Abstract][Full Text] [Related]
20. Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response.
Kasago IS; Chatila WK; Lezcano CM; Febres-Aldana CA; Schultz N; Vanderbilt C; Dogan S; Bartlett EK; D'Angelo SP; Tap WD; Singer S; Ladanyi M; Shoushtari AN; Busam KJ; Hameed M
Mod Pathol; 2023 Aug; 36(8):100165. PubMed ID: 36990277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
